Provided by Tiger Trade Technology Pte. Ltd.

OPKO Health

1.37
-0.0200-1.44%
Pre-market: 1.370.00000.00%07:48 EDT
Volume:2.47M
Turnover:3.38M
Market Cap:1.02B
PE:-14.65
High:1.40
Open:1.37
Low:1.34
Close:1.39
52wk High:1.75
52wk Low:0.9769
Shares:746.33M
Float Shares:324.00M
Volume Ratio:1.21
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0935
EPS(LYR):-0.3005
ROE:-5.88%
ROA:-5.52%
PB:0.86
PE(LYR):-4.56

Loading ...

GUIDANCE: (OPK) OPKO Health Expects 2026 Revenue Range $560M-$585M, vs. FactSet Est of $536.8M

MT Newswires Live
·
Jul 28

Opko Q2 FY26 Net Loss Narrows to $8.4 Million; Revenue Rises to $163.5 Million

Reuters
·
Jul 28

OPKO Health Inc Q3 REV View $134.7 Mln

THOMSON REUTERS
·
Jul 28

OPKO Health Q2 EPS USD -0.01

THOMSON REUTERS
·
Jul 28

OPKO Health: Consolidated Total Revenues for the Second Quarter of 2026 were $163.5 Million

THOMSON REUTERS
·
Jul 28

OPKO Health Q2 EPS $(0.01), Sales $163.500M Beat $131.233M Estimate

Benzinga Earnings
·
Jul 28

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

THOMSON REUTERS
·
Jul 28

3 Promising Penny Stocks With At Least $20M Market Cap

Simply Wall St.
·
Jul 27

OPKO Health Inc Expected to Post a Loss of 8 Cents a Share - Earnings Preview

Reuters
·
Jul 25

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

GlobeNewswire
·
Jul 24

OPKO Health Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since September 2022

Dow Jones
·
Jul 17

OPKO Health (OPK) Ownership Update Draws Attention, Is The 55% Undervalued View Convincing?

Simply Wall St.
·
Jul 03

Opko Health shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
Jun 19

OPKO Health (OPK) Stock Could Be 58.8% Undervalued After OPK8801001 Preclinical Update

Simply Wall St.
·
Jun 17

Entera Bio and Opko Health present preclinical data for oral peptides

TIPRANKS
·
Jun 16

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

GlobeNewswire
·
Jun 16

Opko Health presents preclinical data for weekly acromegaly drug candidate OPK8801001 at ENDO 2026

Reuters
·
Jun 15

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

GlobeNewswire
·
Jun 15

H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK)

TIPRANKS
·
May 27

ModeX Therapeutics to present preclinical in vivo CAR-T generation data at ASGCT 2026

Reuters
·
May 12